XML 20 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
¥ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
CNY (¥)
¥ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
CNY (¥)
¥ / shares
shares
Dec. 31, 2022
CNY (¥)
¥ / shares
shares
Revenues, net of value-added tax ¥ 383,956 $ 52,602 ¥ 537,402 ¥ 472,085
Cost of revenues (463,118) (63,447) (614,010) (624,494)
Gross loss (79,162) (10,845) (76,608) (152,409)
Operating expenses:        
Selling expenses (48,626) (6,662) (56,299) (61,479)
General and administrative expenses (404,372) (55,399) (330,078) (311,160)
Operating loss (532,160) (72,906) (462,985) (525,048)
Interest expense (including interest expense to related party amounting to RMB16,790, RMB14,308 and RMB18,988 (US$2,601) for the years ended December 31, 2022, 2023 and 2024, respectively) (193,199) (26,468) (165,669) (120,357)
Foreign exchange (loss) gain, net (17,468) (2,393) 10,149 54,982
Interest income (including interest income from related party amounting to RMB6,961, RMB6,813 and RMB7,359 (US$1,008) for the years ended December 31, 2022, 2023 and 2024, respectively) 13,982 1,916 10,832 10,021
Change in fair value of derivative liability 166 23 5,207 1,015
Income from equity method investments 12,696 1,739 20,789 17,647
Loss on disposal of a subsidiary 48,497 6,644 (638) (61,546)
Other expenses, net (9,264) (1,269) (10,777) (216,610)
Gain/ (loss) on sale of partial interests in an equity method investment (120) (16) 37,498 0
Changes in fair value of short-term investments 7,290 999 0 0
Loss before income tax (669,580) (91,731) (555,594) (839,896)
Income tax benefit 17,505 2,398 24,573 70,906
Net loss (652,075) (89,333) (531,021) (768,990)
Net loss attributable to noncontrolling interests 343,832 47,105 233,363 279,329
Net loss attributable to Concord Medical Services Holdings Limited ¥ (308,243) $ (42,228) ¥ (297,658) ¥ (489,661)
Loss per share for Class A and Class B ordinary shares:        
Basic | (per share) ¥ (2.35) $ (0.32) ¥ (2.27) ¥ (3.74)
Diluted | (per share) ¥ (2.35) $ (0.32) ¥ (2.27) ¥ (3.74)
Weighted average number of class A and class B ordinary shares outstanding:        
Basic 131,053,858 131,053,858 131,053,858 131,053,858
Diluted 131,053,858 131,053,858 131,053,858 131,053,858
Other comprehensive income (loss), net of tax of nil        
Foreign currency translation, net tax of nil ¥ (7,630) $ (1,045) ¥ (6,480) ¥ (53,964)
Unrealized losses on available-for-sale securities, net (4,299) (589) (31,173)  
Total other comprehensive income (loss), net of tax (11,929) (1,634) (37,653) (53,964)
Comprehensive loss (664,004) (90,967) (568,674) (822,954)
Comprehensive loss attributable to noncontrolling interests (343,832) (47,105) (233,363) (279,329)
Comprehensive loss attributable to Concord Medical Services Holdings Limited (320,172) (43,862) (335,311) (543,625)
Equipment leasing revenues        
Revenues, net of value-added tax 9,356 1,282 16,737 21,966
Cost of revenues (8,034) (1,101) (14,824) (18,905)
Services and other revenues        
Revenues, net of value-added tax 292,455 40,066 420,201 364,412
Cost of revenues (372,063) (50,972) (500,068) (518,500)
Medicine income        
Revenues, net of value-added tax 82,145 11,254 100,464 85,707
Cost of revenues ¥ (83,021) $ (11,374) ¥ (99,118) ¥ (87,089)